Assessment of Anxiety in Clinical Trials with Depressed Patients Using the Hamilton Depression Rating Scale

C Goldberger; J D Guelfi; D V Sheehan

Assessment of Anxiety in Clinical Trials with Depressed Patients Using the Hamilton Depression Rating Scale

Psychopharmacol Bull. 2011 Sep 15;44(3):34-50.

Authors

C Goldberger¹, J D Guelfi¹, D V Sheehan¹

Affiliation

¹ Dr. Goldberger, MD, PhD, Clinical Research Physician, Lilly Research Laboratories, Indianapolis, IN. Dr. Guelfi, MD, Professor of Psychiatry, CMME, Ste Anne Hospital, Paris, France. Dr. Sheehan, MD, MBA, Distinguished University Health Professor, Professor of Psychiatry, Director, Depression and Anxiety Disorders Research Institute, University of South Florida College of Medicine, Tampa, FL.

PMID: 27738361
PMCID: PMC5044547

Abstract

Background: The Hamilton Depression Rating Scale (HAMD₁₇) is an outcome measure widely used in major depressive disorder (MDD) clinical trials. The objective of this analysis was to assess the validity of the anxiety/somatisation factor of the HAMD₁₇ as a measure of anxiety in patients with MDD.

Methods: We pooled data from 1466 outpatients with MDD from four 8-week controlled studies of duloxetine. We performed a factor analysis of the HAMD₁₇ to investigate the anxiety/somatisation factor.

Results: The HAMD₁₇ factor analysis yielded 6 factors, but did not yield the pre-specified anxiety/somatisation factor. This latter factor showed weak correlation with the Hamilton Anxiety Scale total and subscale scores at baseline (0.46), but higher correlation coefficients over the trials up to 0.81. We identified another anxiety factor that included the hypochondriasis item in this sample.

Conclusion: Findings from this large sample suggest that the factor structure of the HAMD₁₇ is unstable in MDD and that the anxiety/somatisation subscale should not be routinely used for anxiety assessment in depressed patients.

Keywords: Anxiety; Depression; Duloxetine; Factor structure; Hamilton.